Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1.480 JPY | +0,89% | -2,18% | +4,15% |
Vakgebied
Aantal werknemers: 350
Verkoop per activiteit
JPY in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Pharmaceutical
100,0
%
| 15 569 | 100,0 % | 12 766 | 100,0 % | -18,00% |
Verkoop per regio
JPY in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Japan
48,4
%
| 80 | 0,5 % | 6 173 | 48,4 % | +7.616,25% |
Switzerland
31,4
%
| 2 564 | 16,5 % | 4 004 | 31,4 % | +56,16% |
United States
10,8
%
| 9 934 | 63,8 % | 1 373 | 10,8 % | -86,18% |
Bermuda
9,5
%
| 2 849 | 18,3 % | 1 212 | 9,5 % | -57,46% |
United Kingdom
0,0
%
| 142 | 0,9 % | 4 | 0,0 % | -97,18% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chris Cargill
CEO | Chief Executive Officer | 40 | 20-09-17 |
Shinichi Tamura
FOU | Founder | 74 | 22-06-90 |
Director of Finance/CFO | - | 24-03-22 | |
Compliance Officer | 70 | 01-04-15 | |
Satoshi Tanaka
PRN | Corporate Officer/Principal | - | 01-07-23 |
Kieran Johnson
AUD | Comptroller/Controller/Auditor | 55 | 24-03-22 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Shinichi Tamura
FOU | Founder | 74 | 22-06-90 |
Noriaki Nagai
BRD | Director/Board Member | 66 | 27-03-19 |
Rolf Soderstrom
BRD | Director/Board Member | 58 | 25-03-20 |
Kuniaki Kaga
BRD | Director/Board Member | 72 | 22-06-18 |
Tomohiro Toyama
BRD | Director/Board Member | 74 | 01-06-11 |
David Roblin
BRD | Director/Board Member | 57 | 22-06-18 |
Chris Cargill
CEO | Chief Executive Officer | 40 | 20-09-17 |
Miwa Seki
BRD | Director/Board Member | 59 | 24-03-22 |
Eiko Tomita
BRD | Director/Board Member | - | - |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 0 | 89 446 777 | 79 495 767 ( 88,87 %) | 335 ( 0,000375 %) | 88,87 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
929 353 | 1.03% | 10 501 689 $ | |
BIOHAVEN LTD. 0.03% | 27 308 | 0.03% | 1 493 475 $ |
NXERA PHARMA CO., LTD. 0.00% | 300 | 0.00% | 3 294 $ |
Bedrijfsgegevens
Sosei Group Corp.
PMO Hanzomon, 11/F 2-1 Koji-machi
102-0083, Tokyo
+81 3 5210 3290
https://soseiheptares.comBedrijven van de groep
Naam | Categorie en sector |
---|---|
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. |
Pharmaceuticals: Major
|
Sector
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+4,15% | 848 mln. | |
-2,68% | 85,68 mld. | |
+4,08% | 41,4 mld. | |
-25,00% | 28,22 mld. | |
+54,31% | 24,64 mld. | |
-4,79% | 16,98 mld. | |
-42,09% | 13,29 mld. | |
-17,52% | 11,66 mld. | |
-12,10% | 11,65 mld. | |
+0,75% | 8,18 mld. |
- Beurs
- Aandelen
- Koers 4565
- Onderneming Nxera Pharma Co., Ltd.